Cargando…

A real-world analysis of survival and cost-effectiveness of sintilimab plus bevacizumab biosimilar regimen in patients with advanced hepatocellular carcinoma

PURPOSE: Programmed death-1 (PD-1) inhibitor sintilimab plus bevacizumab has been approved as the first-line treatment for patients with advanced hepatocellular carcinoma (aHCC). However, the clinical benefits of sintilimab plus bevacizumab in a real-world setting in China is insufficiently defined...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Xianghua, Jia, Yingxin, Chen, Hongmei, Luo, Qinli, Zhao, Huakan, Liang, Guanzhong, Chen, Wen, Li, Yongsheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10185451/
https://www.ncbi.nlm.nih.gov/pubmed/37188985
http://dx.doi.org/10.1007/s00432-023-04775-2
_version_ 1785042359158833152
author Zeng, Xianghua
Jia, Yingxin
Chen, Hongmei
Luo, Qinli
Zhao, Huakan
Liang, Guanzhong
Chen, Wen
Li, Yongsheng
author_facet Zeng, Xianghua
Jia, Yingxin
Chen, Hongmei
Luo, Qinli
Zhao, Huakan
Liang, Guanzhong
Chen, Wen
Li, Yongsheng
author_sort Zeng, Xianghua
collection PubMed
description PURPOSE: Programmed death-1 (PD-1) inhibitor sintilimab plus bevacizumab has been approved as the first-line treatment for patients with advanced hepatocellular carcinoma (aHCC). However, the clinical benefits of sintilimab plus bevacizumab in a real-world setting in China is insufficiently defined to date. This study aims to evaluate the efficacy and cost-effectiveness of sintilimab plus bevacizumab biosimilar in a real-word cohort of patients with aHCC from China. METHODS: We reviewed the clinical data of 112 consecutive patients with aHCC who received sintilimab plus bevacizumab as a first-line treatment in Chongqing University Cancer hospital between July, 2021 and December, 2022. Overall survival, progression-free survival, overall response rate, and adverse event rates were assessed based on the RECIST 1.1. The survival curves were grafted by Kaplan–Meier method. RESULTS: Sixty-eight patients with aHCC were included our study. Efficacy evaluation results showed that 8 patients were partial remission, 51 patients were stable and 9 patients showed progression disease. Median overall survival and progression-free survival were 344.00 (168.77–419.23) days and 238.00 (174.56–301.44) days, respectively. Adverse events occurred in 35 patients (51.5%), including 9 patients with grade ≥ 3. The life-year (LY) and quality-adjusted LY (QALY) were 1.97 and 2.92, respectively, with a cost of $35,018. CONCLUSION: Our data confirmed the promising efficacy, tolerable toxicity and cost-effectiveness in Chinese patients with aHCC who received sintilimab plus bevacizumab as the first-line therapy regimen in real-world practice.
format Online
Article
Text
id pubmed-10185451
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-101854512023-05-17 A real-world analysis of survival and cost-effectiveness of sintilimab plus bevacizumab biosimilar regimen in patients with advanced hepatocellular carcinoma Zeng, Xianghua Jia, Yingxin Chen, Hongmei Luo, Qinli Zhao, Huakan Liang, Guanzhong Chen, Wen Li, Yongsheng J Cancer Res Clin Oncol Research PURPOSE: Programmed death-1 (PD-1) inhibitor sintilimab plus bevacizumab has been approved as the first-line treatment for patients with advanced hepatocellular carcinoma (aHCC). However, the clinical benefits of sintilimab plus bevacizumab in a real-world setting in China is insufficiently defined to date. This study aims to evaluate the efficacy and cost-effectiveness of sintilimab plus bevacizumab biosimilar in a real-word cohort of patients with aHCC from China. METHODS: We reviewed the clinical data of 112 consecutive patients with aHCC who received sintilimab plus bevacizumab as a first-line treatment in Chongqing University Cancer hospital between July, 2021 and December, 2022. Overall survival, progression-free survival, overall response rate, and adverse event rates were assessed based on the RECIST 1.1. The survival curves were grafted by Kaplan–Meier method. RESULTS: Sixty-eight patients with aHCC were included our study. Efficacy evaluation results showed that 8 patients were partial remission, 51 patients were stable and 9 patients showed progression disease. Median overall survival and progression-free survival were 344.00 (168.77–419.23) days and 238.00 (174.56–301.44) days, respectively. Adverse events occurred in 35 patients (51.5%), including 9 patients with grade ≥ 3. The life-year (LY) and quality-adjusted LY (QALY) were 1.97 and 2.92, respectively, with a cost of $35,018. CONCLUSION: Our data confirmed the promising efficacy, tolerable toxicity and cost-effectiveness in Chinese patients with aHCC who received sintilimab plus bevacizumab as the first-line therapy regimen in real-world practice. Springer Berlin Heidelberg 2023-05-16 /pmc/articles/PMC10185451/ /pubmed/37188985 http://dx.doi.org/10.1007/s00432-023-04775-2 Text en © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2023, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Research
Zeng, Xianghua
Jia, Yingxin
Chen, Hongmei
Luo, Qinli
Zhao, Huakan
Liang, Guanzhong
Chen, Wen
Li, Yongsheng
A real-world analysis of survival and cost-effectiveness of sintilimab plus bevacizumab biosimilar regimen in patients with advanced hepatocellular carcinoma
title A real-world analysis of survival and cost-effectiveness of sintilimab plus bevacizumab biosimilar regimen in patients with advanced hepatocellular carcinoma
title_full A real-world analysis of survival and cost-effectiveness of sintilimab plus bevacizumab biosimilar regimen in patients with advanced hepatocellular carcinoma
title_fullStr A real-world analysis of survival and cost-effectiveness of sintilimab plus bevacizumab biosimilar regimen in patients with advanced hepatocellular carcinoma
title_full_unstemmed A real-world analysis of survival and cost-effectiveness of sintilimab plus bevacizumab biosimilar regimen in patients with advanced hepatocellular carcinoma
title_short A real-world analysis of survival and cost-effectiveness of sintilimab plus bevacizumab biosimilar regimen in patients with advanced hepatocellular carcinoma
title_sort real-world analysis of survival and cost-effectiveness of sintilimab plus bevacizumab biosimilar regimen in patients with advanced hepatocellular carcinoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10185451/
https://www.ncbi.nlm.nih.gov/pubmed/37188985
http://dx.doi.org/10.1007/s00432-023-04775-2
work_keys_str_mv AT zengxianghua arealworldanalysisofsurvivalandcosteffectivenessofsintilimabplusbevacizumabbiosimilarregimeninpatientswithadvancedhepatocellularcarcinoma
AT jiayingxin arealworldanalysisofsurvivalandcosteffectivenessofsintilimabplusbevacizumabbiosimilarregimeninpatientswithadvancedhepatocellularcarcinoma
AT chenhongmei arealworldanalysisofsurvivalandcosteffectivenessofsintilimabplusbevacizumabbiosimilarregimeninpatientswithadvancedhepatocellularcarcinoma
AT luoqinli arealworldanalysisofsurvivalandcosteffectivenessofsintilimabplusbevacizumabbiosimilarregimeninpatientswithadvancedhepatocellularcarcinoma
AT zhaohuakan arealworldanalysisofsurvivalandcosteffectivenessofsintilimabplusbevacizumabbiosimilarregimeninpatientswithadvancedhepatocellularcarcinoma
AT liangguanzhong arealworldanalysisofsurvivalandcosteffectivenessofsintilimabplusbevacizumabbiosimilarregimeninpatientswithadvancedhepatocellularcarcinoma
AT chenwen arealworldanalysisofsurvivalandcosteffectivenessofsintilimabplusbevacizumabbiosimilarregimeninpatientswithadvancedhepatocellularcarcinoma
AT liyongsheng arealworldanalysisofsurvivalandcosteffectivenessofsintilimabplusbevacizumabbiosimilarregimeninpatientswithadvancedhepatocellularcarcinoma
AT zengxianghua realworldanalysisofsurvivalandcosteffectivenessofsintilimabplusbevacizumabbiosimilarregimeninpatientswithadvancedhepatocellularcarcinoma
AT jiayingxin realworldanalysisofsurvivalandcosteffectivenessofsintilimabplusbevacizumabbiosimilarregimeninpatientswithadvancedhepatocellularcarcinoma
AT chenhongmei realworldanalysisofsurvivalandcosteffectivenessofsintilimabplusbevacizumabbiosimilarregimeninpatientswithadvancedhepatocellularcarcinoma
AT luoqinli realworldanalysisofsurvivalandcosteffectivenessofsintilimabplusbevacizumabbiosimilarregimeninpatientswithadvancedhepatocellularcarcinoma
AT zhaohuakan realworldanalysisofsurvivalandcosteffectivenessofsintilimabplusbevacizumabbiosimilarregimeninpatientswithadvancedhepatocellularcarcinoma
AT liangguanzhong realworldanalysisofsurvivalandcosteffectivenessofsintilimabplusbevacizumabbiosimilarregimeninpatientswithadvancedhepatocellularcarcinoma
AT chenwen realworldanalysisofsurvivalandcosteffectivenessofsintilimabplusbevacizumabbiosimilarregimeninpatientswithadvancedhepatocellularcarcinoma
AT liyongsheng realworldanalysisofsurvivalandcosteffectivenessofsintilimabplusbevacizumabbiosimilarregimeninpatientswithadvancedhepatocellularcarcinoma